Work

Lasmiditan as a potential targeted therapy for vestibular migraine? A case study

Year: 2025

Type: article

Abstract: Background Vestibular migraine (VM) is a common migraine subtype. Treatment options in the acute stage are limited. Case Here, we present the case of a 53-year-old woman experiencing frequent episodes of sensory aura, as well as vertigo and right-sided headaches lasting between 2 and 9 hours. The patient initially used rizatriptan as acute therapy, which reduced the headaches but not the vertigo. Only the use of lasmiditan led to a reduction in both the headache and the vertigo. Conclusion We hypothesize that in this patient, the vertigo was caused by vasoconstriction and that rizatriptan was unable to reverse this effect due to its selective binding to 5-HT1B receptors, which mediate vasoconstriction. As lasmiditan does not bind to 5-HT1B receptors, it should be evaluated as an option for the acute treatment of VM in larger cohorts.

Source: Cephalalgia Reports

DOI: 10.1177/25158163251397366

Authors: Patrik Theodor Nerdal, Soenke Peters, Walter Maetzler

Institution: University Hospital Schleswig-Holstein

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,500